Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Carcinoma, Medullary 1Adenoma, Islet Cell 1

Interventions

Carboplatin 11pembrolizumab 10Gemcitabine 8Cisplatin 8Rituximab 7osimertinib 5durvalumab 5Specimen Handling 5Pemetrexed 5Nivolumab 5Dexamethasone 5belzutifan 4atezolizumab 4amivantamab 4Prednisone 4Paclitaxel 4Cyclophosphamide 4Bortezomib 4trastuzumab deruxtecan 3olaparib 3lazertinib 3entrectinib 3enfortumab vedotin 3daratumumab 3alectinib 3acalabrutinib 3X-Rays 3Vinorelbine 3Oxaliplatin 3Midazolam 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × cabozantinib × 90 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04211337 2026-03-19

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting
291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡